Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy.

[1]  Baris Turkbey,et al.  Comparison of endorectal coil and nonendorectal coil T2W and diffusion‐weighted MRI at 3 Tesla for localizing prostate cancer: Correlation with whole‐mount histopathology , 2014, Journal of magnetic resonance imaging : JMRI.

[2]  M Emberton,et al.  Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: a paired validating cohort study using template prostate mapping biopsies as the reference standard , 2013, Prostate Cancer and Prostatic Disease.

[3]  Baris Turkbey,et al.  Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. , 2013, European urology.

[4]  P. Choyke,et al.  Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer , 2013, Cancer.

[5]  Baris Turkbey,et al.  Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? , 2013, Radiology.

[6]  J. Ward,et al.  PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. , 2013, The Journal of urology.

[7]  Wim Van Criekinge,et al.  Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. , 2013, The Journal of urology.

[8]  Mark Emberton,et al.  Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. , 2013, European urology.

[9]  H. Parnes,et al.  Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. , 2012, Cancer epidemiology.

[10]  D. Hawkes,et al.  The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation. , 2012, The Journal of urology.

[11]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[12]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[13]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[14]  Baris Turkbey,et al.  Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. , 2011, The Journal of urology.

[15]  G. Haber,et al.  Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging‐targeted and systematic biopsy for significant prostate cancer detection , 2011, BJU international.

[16]  Pingkun Yan,et al.  Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. , 2011, The Journal of urology.

[17]  Yipeng Hu,et al.  Characterizing clinically significant prostate cancer using template prostate mapping biopsy. , 2011, The Journal of urology.

[18]  P. Choyke,et al.  D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. , 2010, The Journal of urology.

[19]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[20]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.